scPharmaceuticals Inc. / Fundamentals
Income statement
- Net revenue
€42.78M - Cost of goods sold
€13.49M - Gross profit
€29.29M - SG&A expenses
€73.05M - R&D expenses
€13.20M - EBITDA
-€70.71M - D&A
-€33.39K - EBIT
-€56.96M - Interest expenses
€2.87M - EBT
-€78.52M - Tax expenses
-€6.61K - Net income
-€78.52M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€22.16M - Changes in working capital
-€5.69M - Operating cash flow
-€56.38M - Capex
€17.98K - Other investing cash flow
€0.00 - Net investing cash flow
-€17.98K - Total cash dividends paid
€0.00 - Issuance of common stock
€46.11M - Debt repayment
€0.00 - Other financing cash flow
€12.39M - Net financing cash flow
€58.37M - Foreign exchange effects
€0.00 - Net change in cash
€1.97M - Cash at end of period
€34.94M - Free cash flow
-€56.36M
Balance sheet
- Cash and cash equivalents
€34.94M - Cash and short-term investments
€34.94M - Total receivables
€16.62M - Inventory
€12.48M - Other current assets
€3.37M - Total current assets
€67.40M - Property, plant & equipment
€1.05M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€259.40K - Total non-current assets
€1.31M - Total assets
€68.71M - Accounts payable
€3.45M - Short-term debt
€226.01K - Other current liabilities
€13.82M - Total current liabilities
€17.49M - Long-term debt
€45.52M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€24.79M - Total non-current liabilities
€69.46M - Total liabilities
€86.95M - Common stock
€4.28K - Retained earnings
-€346.08M - Other equity
€0.00 - Total equity
-€18.25M - Total liabilities and shareholders' equity
€68.71M
Company information
- Market capitalization
€174.26M - Employees
162 - Enterprise Value
€210.20M
Company ratios
- Gross margin
-
68.5% Much better than peer group: -1,201.1% - EBITDA margin
-
-165.3% Much better than peer group: -10,108.5% - EBIT margin
-
-133.2% Much better than peer group: -11,140.7% - EBT margin
-
-183.5% Much better than peer group: -11,060.1% - Net margin
-
-183.5% Much better than peer group: -11,256.1% - ROE
-
430.3% Much better than peer group: -185.3% - ROA
-
-114.3% Much better than peer group: -752.2% - Asset turnover
-
62.3% Much better than peer group: 3.7% - FCF margin
-
-131.8% Much better than peer group: -9,552.9% - FCF yield
-32.4% - Efficiency ratio
265.3% - Net sales per employee
-
€264.06K - Net income per employee
-
-€484.67K